HSDT Share Price | Helius Medical Technologies, Inc. Stock Analysis & Recommendation

Q: How big is Helius Medical Technologies, Inc.?

Market Cap: As of Jun 18, Helius Medical Technologies, Inc. has a market capitalization of 0.16 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Helius Medical Technologies, Inc. reported net sales of 0.43 million and a net profit of -13.07 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1.06 million and total assets of 3.54 million.

Q: What does Helius Medical Technologies, Inc. do?

Overview: Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 0.16 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.87 Return on Equity: -1,169.69% Price to Book: 0.13Contact Details: Address: 642 Newtown Yardley Road, NEWTOWN PA: 18940 Tel: 1 215 9446104 Fax: 1 302 6555049 Website: https://heliusmedical.com/

Q: Is Helius Medical Technologies, Inc. overvalued or undervalued?

As of 12 August 2020, Helius Medical Technologies, Inc. has moved from a grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, particularly given its negative financial ratios. Notably, the Price to Book Value stands at 0.45, while both the EV to EBIT and EV to EBITDA ratios are at 0.04, reflecting a lack of profitability. The Return on Equity (ROE) is alarmingly low at -1169.69%, which underscores the company's struggle to generate returns for shareholders.In comparison to its peers, Helius Medical Technologies shows a stark contrast with companies like Seastar Medical Holding Corp. and BioRestorative Therapies, which also do not qualify but have less severe financial metrics. The overall peer comparison indicates that Helius is lagging significantly behind, with a valuation of -0.0109 for its EV to EBITDA ratio, compared to peers that are also in the negative range but not as extreme. Furthermore, the company's stock performance has been dismal, with a year-to-date return of -96.82%, starkly underperforming the S&P 500's 2.44% return in the same period.

Q: Is Helius Medical Technologies, Inc. technically bullish or bearish?

As of 14 July 2025, the technical trend for Helius Medical Technologies, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD readings are mildly bullish. However, the overall sentiment is tempered by the Bollinger Bands and KST showing mildly bearish and bearish signals respectively on the monthly timeframe. Despite the bullish signals in the On-Balance Volume, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -95.39% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

359.51 k

Shareholding (Sep 2025)

FII

27.24%

Held by 12 FIIs

DII

72.74%

Held by 1 DIIs

Promoter

0.00%

How big is Helius Medical Technologies, Inc.?

22-Jun-2025

As of Jun 18, Helius Medical Technologies, Inc. has a market capitalization of 0.16 million, with net sales of 0.43 million and a net profit of -13.07 million over the last four quarters. The company reported shareholder's funds of 1.06 million and total assets of 3.54 million as of Dec 24.

View full answer

What does Helius Medical Technologies, Inc. do?

22-Jun-2025

Helius Medical Technologies, Inc. is a micro-cap medical technology company focused on neurological wellness, with recent net sales of $0 million and a net loss of $4 million. The company has a market cap of $0.16 million and operates within the Pharmaceuticals & Biotechnology industry.

View full answer

Is Helius Medical Technologies, Inc. overvalued or undervalued?

25-Jun-2025

Helius Medical Technologies, Inc. is currently considered overvalued and financially unhealthy, with a negative Return on Equity of -1169.69% and a year-to-date stock performance decline of -96.82%, significantly underperforming its peers and the S&P 500.

View full answer

Is Helius Medical Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of July 14, 2025, Helius Medical Technologies, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly MACD readings are mildly bullish, despite significant underperformance against the S&P 500 with a year-to-date return of -95.39%.

View full answer

Compare Helius Medical Technologies, Inc. with Similar Stocks

Vivos Therapeutics, Inc.Aethlon Medical, Inc.NeuroMetrix, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 90 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.81

Return on Equity

138.72%

Price to Book

-0.59

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Sep 2025)

Net Profit:

-353 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.67%

6 Months

-84.44%

1 Year

-99.3%

2 Years

-99.95%

3 Years

747.06%

4 Years

-100.0%

5 Years

-100.0%

Helius Medical Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.71%

EBIT Growth (5y)

1.57%

EBIT to Interest (avg)

-16.83

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.21

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

34.13%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.59

EV to EBIT

2.19

EV to EBITDA

2.19

EV to Capital Employed

0.12

EV to Sales

-33.60

PEG Ratio

Dividend Yield

ROCE (Latest)

5.55%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.02%)

Foreign Institutions

Held by 12 Foreign Institutions (27.24%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -3,500.00% vs -157.89% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-3.30",
          "chgp": "-48.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "194.70",
          "val2": "0.60",
          "chgp": "32,350.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-153.00",
          "val2": "-6.00",
          "chgp": "-2,450.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-352.80",
          "val2": "-9.80",
          "chgp": "-3,500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,044.50%",
          "val2": "-77,255.80%",
          "chgp": "7,021.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.67% vs -25.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.46% vs 36.88% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.80",
          "val2": "-12.10",
          "chgp": "-14.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.90",
          "val2": "2.80",
          "chgp": "3.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.70",
          "val2": "-8.90",
          "chgp": "-31.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-26,659.60%",
          "val2": "-19,051.20%",
          "chgp": "-760.84%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.70

0.00

Operating Profit (PBDIT) excl Other Income

-4.90

-3.30

-48.48%

Interest

194.70

0.60

32,350.00%

Exceptional Items

-153.00

-6.00

-2,450.00%

Consolidate Net Profit

-352.80

-9.80

-3,500.00%

Operating Profit Margin (Excl OI)

-7,044.50%

-77,255.80%

7,021.13%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -3,500.00% vs -157.89% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

0.60

-16.67%

Operating Profit (PBDIT) excl Other Income

-13.80

-12.10

-14.05%

Interest

0.00

Exceptional Items

2.90

2.80

3.57%

Consolidate Net Profit

-11.70

-8.90

-31.46%

Operating Profit Margin (Excl OI)

-26,659.60%

-19,051.20%

-760.84%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -16.67% vs -25.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -31.46% vs 36.88% in Dec 2023

All Annual Results

Company CV

About Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc.

Pharmaceuticals & Biotechnology

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company’s offered product is portable neuromodulation stimulator (PoNS) device. PoNS is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation.

Company Coordinates

Company Details

642 Newtown Yardley Road , NEWTOWN PA : 18940

Tel: 1 215 9446104

https://heliusmedical.com/

Registrar Details